We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

110 hedge funds and large institutions have $136M invested in Insys Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 28 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

44% more capital invested

Capital invested by funds: $94.2M → $136M (+$41.3M)

17% more call options, than puts

Call options by funds: $5.49M | Put options by funds: $4.68M

12% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 25

7% more funds holding

Funds holding: 103110 (+7)

Holders
110
Holders Change
+7
Holders Change %
+6.8%
% of All Funds
2.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
28
Reduced
25
Closed
11
Calls
$5.49M
Puts
$4.68M
Net Calls
+$806K
Net Calls Change
+$3.44M
Name Holding Trade Value Shares
Change
Change in
Stake
BFM
26
Boothbay Fund Management
New York
$621K +$491K +61,600 New
TA
27
Teachers Advisors
New York
$562K -$3.73K -467 -0.8%
TCIM
28
TIAA CREF Investment Management
New York
$534K -$12.9K -1,619 -3%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$415K
Swiss National Bank
30
Swiss National Bank
Switzerland
$407K
CWM
31
Cornerstone Wealth Management
Missouri
$400K +$27.6K +3,464 New
WMSA
32
Weiss Multi-Strategy Advisers
New York
$353K -$70.4K -8,830 -20%
Invesco
33
Invesco
Georgia
$341K +$854 +107 +0.3%
ProShare Advisors
34
ProShare Advisors
Maryland
$338K -$7.93K -994 -3%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$306K -$439 -55 -0.2%
DekaBank Deutsche Girozentrale
36
DekaBank Deutsche Girozentrale
Germany
$304K -$3.99K -500 -2%
AIM
37
Assured Investment Management
New York
$284K +$189K +23,703 +534%
JG
38
Jefferies Group
New York
$270K -$195K -24,423 -48%
Bank of America
39
Bank of America
North Carolina
$259K +$138K +17,252 +205%
UBS Group
40
UBS Group
Switzerland
$258K +$108K +13,591 +113%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$254K -$13.8K -1,725 -6%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$229K
PPA
43
Parametric Portfolio Associates
Washington
$221K +$17K +2,129 +11%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$192K
State Board of Administration of Florida Retirement System
45
State Board of Administration of Florida Retirement System
Florida
$180K
AIG
46
American International Group
New York
$180K +$2.56K +321 +2%
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
$153K +$12.6K +1,580 +12%
Creative Planning
48
Creative Planning
Kansas
$153K +$121K +15,205 New
Janney Montgomery Scott
49
Janney Montgomery Scott
Pennsylvania
$147K +$17.5K +2,200 +18%
MIM
50
MetLife Investment Management
New Jersey
$142K +$113K +14,114 New

INSY Hedge Fund Activity: Q3 2018 in Review

110 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2018, worth a combined $136M — up 44% from $94.2M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new INSY positions and 11 closed out — a net gain of 7 holders — while 28 added to existing stakes and 25 trimmed.

The largest buyer was Norges Bank, adding an estimated $1.75M. The largest seller was OrbiMed, cutting an estimated $3.85M.

  • 110 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2018, up from 103 in Q2 2018.
  • Funds reported $136M of Insys Therapeutics, Inc. stock for Q3 2018, up 44% quarter-over-quarter.
  • 18 funds opened new Insys Therapeutics, Inc. positions in Q3 2018 and 11 closed out, a net change of +7 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2018 was Norges Bank, an estimated $1.75M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2018 was OrbiMed, an estimated $3.85M sold.

Based on aggregated 13F filings for Q3 2018.